Association Between Endogenous Equol Production and the Onset of Overactive Bladder in Postmenopausal Women
- PMID: 40565929
- PMCID: PMC12193917
- DOI: 10.3390/jcm14124183
Association Between Endogenous Equol Production and the Onset of Overactive Bladder in Postmenopausal Women
Abstract
Objectives: Equol, a gut-derived metabolite of soy isoflavones with estrogenic activity, may influence bladder aging. However, the association between overactive bladder (OAB), which is closely linked to bladder aging, and the estrogenic effects of equol remains unknown. Therefore, this study investigated the association between endogenous equol production and onset and severity of OAB in postmenopausal women. Methods: The study included 128 postmenopausal women, newly diagnosed with OAB, who were categorized into equol- and non-equol-producing groups based on urinary equol levels as measured by enzyme-linked immunosorbent assay. Patient clinical characteristics, OAB Symptom Score (OABSS), and urodynamic parameters were assessed. Propensity score matching was performed to minimize confounding factors related to the timing of lower urinary tract symptom (LUTS) onset. Results: Equol producers exhibited a significantly later onset of LUTS than non-producers (68.7 ± 10.9 vs. 62.7 ± 10.7 years, p = 0.002). Equol producers were more prevalent in the late-onset group (58.6% vs. 31.0%, p = 0.002), which had significantly higher urinary equol concentrations than the early-onset group (p = 0.014). No significant differences were observed in total OABSS or subscale scores between the groups, suggesting that equol did not affect symptom severity. Propensity score-matched analysis (n = 104) confirmed that equol non-production was an independent risk factor for early-onset LUTS (OR, 1.930; 95% CI, 1.248-4.049; p = 0.014). Conclusions: Endogenous equol production was significantly associated with the delayed onset of OAB in postmenopausal women. Thus, equol may serve as a protective factor and non-invasive biomarker to guide individualized prevention and early intervention strategies in urological care for women.
Keywords: equol; lower urinary tract symptom; menopause; overactive bladder; women.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Bladder training for treating overactive bladder in adults.Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD013571. doi: 10.1002/14651858.CD013571.pub2. Cochrane Database Syst Rev. 2023. PMID: 37811598 Free PMC article.
-
Surgery for women with pelvic organ prolapse with or without stress urinary incontinence.Cochrane Database Syst Rev. 2018 Aug 19;8(8):CD013108. doi: 10.1002/14651858.CD013108. Cochrane Database Syst Rev. 2018. PMID: 30121956 Free PMC article.
-
Botulinum toxin injections for adults with overactive bladder syndrome.Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Cochrane Database Syst Rev. 2011. PMID: 22161392
-
Electrical stimulation with non-implanted electrodes for overactive bladder in adults.Cochrane Database Syst Rev. 2016 Dec 9;12(12):CD010098. doi: 10.1002/14651858.CD010098.pub4. Cochrane Database Syst Rev. 2016. PMID: 27935011 Free PMC article.
-
Acupuncture for treating overactive bladder in adults.Cochrane Database Syst Rev. 2022 Sep 23;9(9):CD013519. doi: 10.1002/14651858.CD013519.pub2. Cochrane Database Syst Rev. 2022. PMID: 36148895 Free PMC article.
References
-
- Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A., Standardisation Sub-Committee of the International Continence Society The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society. Neurourol. Urodyn. 2002;21:167–178. doi: 10.1002/nau.10052. - DOI - PubMed
-
- Mitsui T., Sekido N., Masumori N., Haga N., Omae K., Saito M., Kubota Y., Sakakibara R., Yoshida M., Takahashi S. Prevalence and impact on daily life of lower urinary tract symptoms in Japan: Results of the 2023 Japan Community Health Survey (JaCS 2023) Int. J. Urol. 2024;31:747–754. doi: 10.1111/iju.15454. - DOI - PMC - PubMed
-
- Ramezani Tehrani F., Mousavi M., Saei Ghare Naz M., Noroozzadeh M., Azizi F., Farahmand M. Endogenous estrogen exposure and hypertension risk; A population-based cohort study with about 2 decades of follow-up. J. Clin. Endocrinol. Metab. 2025;110:e1125–e1133. doi: 10.1210/clinem/dgae316. - DOI - PubMed
LinkOut - more resources
Full Text Sources